Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
118 hedge funds and large institutions have $279M invested in Adverum Biotechnologies in 2021 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 45 increasing their positions, 29 reducing their positions, and 35 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 29
0% less call options, than puts
Call options by funds: $4.26M | Put options by funds: $4.27M
1.63% less ownership
Funds ownership: 9.72% → 8.09% (-1.6%)
11% less funds holding
Funds holding: 132 → 118 (-14)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
37% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 35
70% less capital invested
Capital invested by funds: $937M → $279M (-$658M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$23.2M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$8.76M |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$4.84M |
| 4 |
Two Sigma Investments
New York
|
+$4.52M |
| 5 |
BlackRock
New York
|
+$4.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$92.3M |
| 2 |
O
OrbiMed
New York
|
-$54.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$24.4M |
| 4 |
CC
Casdin Capital
New York
|
-$21.8M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$14.8M |
ADVM Hedge Fund Activity: Q2 2021 in Review
118 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q2 2021, worth a combined $279M — down 70% from $937M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of ADVM and 22 opened new positions — a net loss of 13 holders — while 29 trimmed existing stakes and 45 added.
The largest buyer was State Street, adding an estimated $23.2M. The largest seller was RA Capital Management, exiting entirely with an estimated $92.3M sold.
- 118 institutional investors held Adverum Biotechnologies (ADVM) as of Q2 2021, down from 132 in Q1 2021.
- Funds reported $279M of Adverum Biotechnologies stock for Q2 2021, down 70% quarter-over-quarter.
- 22 funds opened new Adverum Biotechnologies positions in Q2 2021 and 35 closed out, a net change of -13 holders.
- The largest Adverum Biotechnologies buyer in Q2 2021 was State Street, an estimated $23.2M added.
- The largest Adverum Biotechnologies seller in Q2 2021 was RA Capital Management, an estimated $92.3M sold.
Based on aggregated 13F filings for Q2 2021.